KIRhub 2.0· v2

Infigratinib

c750c793-44ce-5d1e-b0fd-bb22171cf38d · FDA Approval Withdrawn · targets FGFR2

Infigratinib

MeasuredReference

Infigratinib targets FGFR1, FGFR2, CSF1R. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

FGFR1 FGFR2 CSF1R FGFR3 FGFR4

Top hallmarks

tumor promoting inflammation2.3k
proliferation2.1k
evading apoptosis1.8k

Top pathways disrupted

pi3k akt mtor signaling5.2k
apical junction5.0k
allograft rejection4.8k

Resistance landscape — Infigratinib

MeasuredReference

10 known oncogenic variants exist on Infigratinib's top targets — see detail for inhibition impact.

FGFR1 2 known variants
- FGFR1 (V561M)
- FGFR1 (W666R)
FGFR2 8 known variants

Open in new tab